en <p style="text-align:justify"><span style="font-size:11pt"><span style="font-size:9.5pt">Background:</span><span style="font-size:10.0pt"> Nuclear factor-erythroid 2-related factor 2 (Nrf2) plays a key role in promoting chemoresistance in various cancers. PD-L1 is one of the downstream targets of the Nrf2 signaling pathway. This molecule has some beneficial impacts on tumors growth by inhibition of the immune system. This study aimed to investigate the potential role of the Nrf2-PD-L1 axis in the promotion of oxaliplatin resistance in colon cancer cells. </span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-size:9.5pt">Methods</span><span style="font-size:10.0pt">:</span> <span style="font-size:10.0pt">We examined Nrf2, PD- L1, and CD80 expression in the tumor and margin tissue samples from CRC patients. After that role of the Nrf2-PD-L1 axis in promotion of Oxaliplatin </span><span style="font-size:10.0pt">resistance </span><span style="font-size:10.0pt">was investigated.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-size:9.5pt">Results:</span><span style="font-size:10.0pt"> Our data revealed that Nrf2 and PD-L1 mRNA expressions were markedly higher in tumor tissues compared to margin tissues. The PD-L1 mRNA expression level was also increased in the resistant cells. However, Nrf2 expression was decreased in SW480/Res cells and increased in LS174T/Res cells. The inhibition of Nrf2 through siRNA treatment in SW480/Res and LS174T/Res cells has decreased the IC50 values of oxaliplatin. Inhibition of the Nrf2 has significantly increased the oxaliplatin-induced apoptosis, and reduced the migration in SW480/Res cells. </span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-size:9.5pt">Conclusion:</span><span style="font-size:10.0pt"> It is suggested that effective inhibition of Nrf2-PD-L1 signaling pathways can be considered as a novel approach to improve oxaliplatin efficacy in colon cancer patients. </span></span></p> Colonic neoplasms, Humans, NF-E2-Related Factor 2, Oxaliplatin, Signal transduction 116 122 https://www.ajmb.org/En/Article.aspx?id=40463 https://www.ajmb.org/PDF/En/FullText/40463.pdf ZahraPayandehImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran61767AbbasPirpour TazehkandDepartment of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran, Tabriz, Iran61768BehzadMansooriDrug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran61769VahidKhazeImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran61770MiladAsadiImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran61771BehzadBaradaran868NasserSamadi 61773